Compounded GLP-1 availability in 2026: who's still shipping, who's stopped
On April 30, 2026 the FDA proposed permanently ending mass compounding of semaglutide and tirzepatide, issued 30 warning letters, and opened a comment period through June 29. Hims already exited. Here's who's still operating and what to do.
By GLPZoom Editorial
2 min readUpdated
The compounding gold rush is ending, and 2026 is the year it accelerated. After the FDA declared semaglutide off the shortage list in late 2024 and tirzepatide in early 2025, the agency went further on April 30, 2026: it proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding list, issued 30 warning letters, and opened a public comment period through June 29, 2026. Hims & Hers exited compounded GLP-1s entirely in February 2026. The picture is now less 'who's cheapest' and more 'who's still legally allowed to ship'.
Who's still shipping
Three categories remain. First: pharmacies producing custom formulations with clinically justified modifications — a different dose, an excipient swap for allergy, an oral troche instead of injection. These remain legal under 503A rules when the prescribing clinician documents the medical necessity.
Second: 503B outsourcing facilities, which operate under stricter FDA oversight. A handful supply telehealth platforms with branded-equivalent products under the 'commercially manufactured drug shortage' exception, which the FDA reinterpreted narrowly but didn't eliminate.
Third: telehealth platforms that switched entirely to branded prescribing (Wegovy, Zepbound) with patient-assistance programs that bring the effective cost down to $200-500/month for self-pay patients.
What this means for you
If you're currently on a compounded program, ask your provider three questions: is the formulation a custom medical necessity or a commercial substitute (the former is more legally stable); what's the pharmacy's regulatory tier (503A vs 503B); and do they have a transition plan if the FDA tightens further.
If you're considering starting, the cost gap between branded and compounded has narrowed considerably. The math used to be $1300/month branded vs $300/month compounded. It's now closer to $400 branded vs $250 compounded for many platforms. The compounded discount no longer justifies the regulatory risk for most patients.
Related reads
Wegovy prior authorization: the step-by-step approval playbook (2026)
Wegovy denials usually come from incomplete documentation, not clinical ineligibility. Here's the exact step-by-step process that gets approval on the first submission, plus what to do when denied.
GLP-1 hair loss timeline: when it starts, peaks, and recovers (2026)
Hair shedding on Wegovy, Ozempic, or Zepbound follows a predictable pattern tied to rapid weight loss, not the drug itself. Here's the week-by-week timeline, why it happens, and what actually shortens recovery.
Wegovy vs Ozempic in 2026: same drug, different prescribing rules
Wegovy and Ozempic are both semaglutide. Wegovy is FDA-approved for weight management; Ozempic for type 2 diabetes. Same active ingredient — but different dose, different insurance pathway, different cost, and different clinical conversation. Here's the full comparison.